Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Division of Cancer Prevention, National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. British journal of cancer 108(3), 479–485 (2013).
2. Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Reviews Cancer 12(5), 323–334 (2012).
3. Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nature medicine 22(1), 105–113 (2016).
4. Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nature reviews. Clinical oncology 13(6), 335–347 (2016).
5. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467), 338–345 (2013).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献